AAP
CRVO icon

Arax Advisory Partners’s CervoMed CRVO Stock Holding History

Arax Advisory Partners’s Portfolio CRVO Stock Details CRVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$20 Buy
14
+9
+180% +$47 ﹤0.01% 3717
2025
Q4 		$40 Sell
5
-27
-84% -$217 ﹤0.01% 3955
2025
Q3 		$258 Buy
+32
New +$275 ﹤0.01% 3430

Other funds holding CRVO

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
CFG
Citizens Financial Group Providence, Rhode Island $7.19B AUM 23.93% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Arax Advisory Partners's CRVO Position: Q1 2026 in Review

Arax Advisory Partners increased its CervoMed (CRVO) stake by 180% in Q1 2026, buying an estimated $47 and bringing the position to 14 shares worth $20. The position accounts for ﹤0.01% of the portfolio, ranked #3717.

Arax Advisory Partners first reported a position in CRVO in Q3 2025 and has held it in 3 quarters since. The position peaked at $258 in Q3 2025. 36 funds tracked by Wall St. Rank hold CRVO as of Q1 2026.

  • Arax Advisory Partners held 14 shares of CervoMed worth $20 as of Q1 2026.
  • Arax Advisory Partners bought 9 CervoMed shares in Q1 2026, an estimated $47.
  • CervoMed made up ﹤0.01% of Arax Advisory Partners's portfolio in Q1 2026, its #3717 holding.
  • Arax Advisory Partners first reported a position in CervoMed in Q3 2025 and has held it in 3 quarters since.
  • Arax Advisory Partners's CervoMed position peaked at $258 in Q3 2025.
  • 36 funds tracked by Wall St. Rank held CervoMed as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.